Browse Studies — Arctuva

Phase 3

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamid…

Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate Cancer+1 more

Estimated

~$10 – $7,500

PfizerNCT07028853

Phase 1

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PE…

Prostate CancerCastration Sensitive Prostate CancerMetastatic Prostate Cancer+1 more

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT07674771

Phase 1

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to…

Castration Sensitive Prostate Cancer

Estimated

~$10 – $6,250

University of ArkansasNCT06044025

Phase 4

Modulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal Therapy

This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensiti…

Castration Resistant Prostate CancerCastration Sensitive Prostate CancerProstate Adenocarcinoma

Estimated

~$10 – $7,500

OHSU Knight Cancer InstituteNCT05919329